The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965), AHA-supported legislation that would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. Previously passed by the Energy and Commerce Committee, the bill could next move to the floor.
 
In other action yesterday, the Judiciary Committee approved bipartisan bills to strengthen the Federal Trade Commission’s ability to challenge anticompetitive pay-for-delay agreements in court (H.R. 2375); reduce incentives for brand name drug makers to interfere with the regulatory approval of generics and biosimilars (H.R. 2374); and require the FTC to study competition in the drug supply chain (H.R. 2376).

Related News Articles

Headline
The House Energy and Commerce Committee March 12 passed AHA-supported  legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care Provider…
Headline
The Senate voted 75-22 on March 8 to pass and send to the president for his signature a package of six appropriations bills funding certain federal agencies…
Headline
The House March 5 voted 382-12 to pass the AHA-supported Preventing Maternal Deaths Reauthorization Act (H.R. 3838), bipartisan legislation that would…
Headline
The House Ways and Means Committee March 6 voted 26-17 to advance as amended to the full House the Protecting America’s Seniors’ Access to Care Act (H.R. 7513…
Headline
The House March 6 voted 339-85 to pass a package of six appropriations bills that would fund certain federal agencies through fiscal year 2024 and contains…
Headline
The House and Senate Appropriations Committees March 3 released a package of six appropriations bills that would fund certain federal agencies through fiscal…